KLOW Peptide Research Blend

Key facts

01 What is the KLOW peptide blend?

The KLOW peptide blend puts several separate peptides into one vial. Vinnix sells it as KLOW80, 80 mg in total. Whether someone searches klow, klow blend or klow peptide blend, this is the kind of product they mean. KLOW is just a catalog name; it describes no effect.

In the research-peptide market, KLOW usually refers to a four-component mix of GHK-Cu, TB-500, BPC-157 and KPV. In other words, the GLOW formulation with KPV added. But market usage isn't a specification. For the Vinnix product, the KLOW80 product record and each batch's certificate of analysis will be the authoritative sources for components and amounts.

02 KLOW blend composition and quantity of each compound

The KLOW peptide blend's composition, including how much of each component it holds, will be stated on the Vinnix KLOW80 product record and reported on each batch COA. The table lists the compounds most often tied to the KLOW name so you can compare them against the batch paperwork.

03 Each compound commonly found in KLOW

These are four separate molecules. Each one has its own identity data, its own literature and its own full Vinnix compound page.

GHK-Cu

GHK-Cu is the copper(II) complex of the tripeptide Gly-His-Lys, 402.9 g/mol according to PubChem (CID 71587328). GHK was first reported in human serum in 1973 ^[1], and X-ray methods have since solved its copper-binding structure ^[2]. Full entry: GHK-Cu.

TB-500

TB-500 is a trade name for a synthetic peptide related to thymosin beta-4, a 43-amino-acid protein sequenced in 1981 ^[3]. Some TB-500 materials carry the full sequence, others a fragment, and fragments of thymosin beta-4 are studied as molecules in their own right ^[4]. Full entry: TB-500.

BPC-157

BPC-157 is a 15-amino-acid synthetic peptide, GEPPPGKPADDAGLV, weighing 1419.5 g/mol as the free peptide (PubChem CID 9941957). Most of its literature is in vitro and animal work ^[5][6]. Full entry: BPC-157.

KPV

KPV is the tripeptide Lys-Pro-Val (C₁₆H₃₀N₄O₄, 342.4 g/mol, PubChem CID 125672, CAS 67727-97-3). It matches residues 11 to 13 of alpha-melanocyte-stimulating hormone and has been examined next to the parent hormone in cultured human keratinocyte cells ^[7]. Full entry: KPV.

04 How is KLOW different from GLOW?

In market usage, the main difference is that the KLOW peptide blend adds KPV, which would also explain its larger total quantity. The Vinnix comparison follows. For KLOW80, the component list that counts is the one on its own product record and batch COA when published.

Documentation for the three-component product, including its own component list, is on the GLOW peptide blend page.

05 Why do these compounds appear together in research?

They show up together because each one has its own laboratory and animal literature. Nobody has studied the combination as a single product, as far as we know: we are not aware of a peer-reviewed controlled study of a KLOW-type blend.

• GHK-Cu: serum isolation and copper-binding chemistry ^[1][2] (in vitro, structural)
• Thymosin beta-4 and its fragments: sequencing and active-site work ^[3][4] (biochemical, review)
• BPC-157: cell-culture work plus a systematic review of mostly preclinical evidence ^[5][6]
• KPV: signalling studies in human keratinocyte cell lines ^[7] (in vitro)

Keep the study types in mind (in vitro vs. in vivo research explains them): none of this preclinical work establishes safety or effectiveness in humans.

06 How is a multi-component klow peptide blend analyzed?

With four likely components, the KLOW peptide blend makes the strongest case in the catalog for component-level testing. One purity figure for the vial would average four very different molecules into a number that describes none of them. A lab needs an identity result and a quantity result for each peptide, two separate questions that identity vs. purity unpacks. The general methods are covered in peptide testing and analysis.

1. Resolve the peaks. The HPLC method has to pull every listed component apart, including the two small tripeptides that tend to leave the column early.
2. Assign each peak. Mass spectrometry reads the mass under each peak and matches it to one component. Run online as LC-MS, separation and assignment happen together.
3. Measure each amount. Every component is quantified against its own reference standard, so the COA can show one amount per peptide rather than a single total.
4. Check each impurity profile. Related impurities are tracked per component. A clean combined trace can still hide a degraded minor component.

The compounds commonly listed for the KLOW peptide blend cover a wide mass range (see what is molecular weight): KPV at about 342 g/mol, GHK-Cu at about 403 g/mol, BPC-157 at 1419.5 g/mol and TB-500 at up to about 4963 g/mol. Mass spectrometry benefits from that spread. HPLC is trickier, since the two small components can elute early and close together, so the method has to be shown to resolve every listed component.

07 KLOW blend COA and batch documentation

Every batch of the KLOW peptide blend (KLOW80) will get its own certificate of analysis, and the batch number on it should match your vial. For a four-part blend, look for a report that breaks results out by component instead of summarizing the vial. Reports will appear in the Vinnix COA Library, searchable by product, SKU and batch, once published. Expect each one to cover:

• Product name, SKU and a batch or lot number identical to the vial label
• The component list, with a mass spectrometry identity result for each entry
• The amount of each component, not just the 80 mg total
• An HPLC chromatogram with each peak assigned to a component
• The testing laboratory, test date and methods

If a field is unclear, how to read a peptide COA takes it line by line, and what a certificate of analysis is sets out the limits of any COA.

REFScientific references

1. Pickart L, Thaler MM. Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver. Nat New Biol. 1973;243(124):85-7. PubMed 4349963
   in vitro study
2. Hureau C, Eury H, Guillot R, et al. X-ray and solution structures of Cu(II) GHK and Cu(II) DAHK complexes: influence on their redox properties. Chemistry. 2011;17(36):10151-60. PubMed 21780203
   in vitro (structural chemistry) study
3. Low TL, Hu SK, Goldstein AL. Complete amino acid sequence of bovine thymosin beta 4: a thymic hormone that induces terminal deoxynucleotidyl transferase activity in thymocyte populations. Proc Natl Acad Sci U S A. 1981;78(2):1162-6. PubMed 6940133
   in vitro (protein sequencing) study
4. Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J. 2010;24(7):2144-51. PubMed 20179146
   review
5. Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-77. PubMed 25415472
   in vitro study
6. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495. PubMed 40756949
   systematic review
7. Elliott RJ, Szabo M, Wagner MJ, et al. alpha-Melanocyte-stimulating hormone, MSH 11-13 KPV and adrenocorticotropic hormone signalling in human keratinocyte cells. J Invest Dermatol. 2004;122(4):1010-9. PubMed 15102092
   in vitro study